MEPS & Military Drug Testing

Evidence-based answer reviewed against SAMHSA cutoffs and FDA assay documentation · Updated August 2026

Quick answer: MEPS entry screens urine on ship-day; service-phase DoD urinalysis continues throughout — admitted prior use follows waiver paths, detected use ends contracts.

Entry screening

MEPS runs a urine panel (marijuana/cocaine/amphetamines/PCP/opiates ± ecstasy) on ship-day; prior-USE disclosures during processing protect you — ADMITTED experimentation follows waiver pathways, DETECTED use ends enlistment contracts.

Service-phase testing

DoD urinalysis hits every unit randomly (monthly-ish patterns vary); positive THC = separation processing typically for first offenses now, harder-drug positives end careers faster. No state-legalization defense exists on federal installations.

Prior-use honesty math

Recruiters counsel disclosure windows: admitted-and-waivered beats detected-and-discharged in essentially every scenario. Hair testing ISN'T standard at MEPS — urine windows define entry risk.

Certified labs nationwide · Results in 1–2 days

Need a test? Order online, test same-day →
Medical disclaimer: DrugPanels provides educational information about laboratory drug testing and does not offer medical advice, diagnosis, or treatment. Detection windows are population ranges — individual results vary with metabolism, dose, frequency and health status. Never stop prescribed medication to pass a test without talking to your prescriber. Affiliate disclosure: some links on this page are affiliate links; if you order through them we may earn a commission at no additional cost to you.

People also ask

Do prescriptions count against me?

No — verified prescriptions report as negative through the Medical Review Officer. Declare medications at collection and answer the follow-up call.

Sources & further reading

  • SAMHSA — Mandatory Guidelines for Federal Workplace Drug Testing Programs (cutoffs, MRO process)
  • DOT — 49 CFR Part 40 procedures for transportation workplace testing
  • Brahm NC et al., Mayo Clinic Proceedings 2008;83(1):66–76 — false-positive cross-reactivity reference
  • FDA — drug-of-abuse test device labeling (detection window conventions)